Rice Hall James & Associates LLC Reduces Stock Holdings in Azenta, Inc. (NASDAQ:AZTA)

Rice Hall James & Associates LLC decreased its position in Azenta, Inc. (NASDAQ:AZTA) by 1.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 40,971 shares of the company’s stock after selling 437 shares during the period. Rice Hall James & Associates LLC’s holdings in Azenta were worth $1,985,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the company. Nisa Investment Advisors LLC lifted its stake in Azenta by 1.9% in the third quarter. Nisa Investment Advisors LLC now owns 36,710 shares of the company’s stock valued at $1,778,000 after purchasing an additional 700 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its position in shares of Azenta by 16.4% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,298,856 shares of the company’s stock worth $62,917,000 after acquiring an additional 183,040 shares in the last quarter. Net Worth Advisory Group purchased a new stake in shares of Azenta during the third quarter worth $205,000. Wesbanco Bank Inc. lifted its position in shares of Azenta by 72.2% during the third quarter. Wesbanco Bank Inc. now owns 31,000 shares of the company’s stock worth $1,502,000 after acquiring an additional 13,000 shares in the last quarter. Finally, Procyon Advisors LLC purchased a new stake in shares of Azenta during the third quarter worth $247,000. Hedge funds and other institutional investors own 99.08% of the company’s stock.

Azenta Stock Up 0.3 %

AZTA opened at $41.22 on Friday. The stock has a market cap of $2.02 billion, a PE ratio of -14.67 and a beta of 1.47. Azenta, Inc. has a 52 week low of $40.24 and a 52 week high of $69.16. The business’s fifty day simple moving average is $46.31 and its 200 day simple moving average is $50.93.

Azenta (NASDAQ:AZTA) last released its earnings results on Tuesday, August 6th. The company reported $0.16 EPS for the quarter, beating analysts’ consensus estimates of $0.07 by $0.09. The business had revenue of $173.00 million for the quarter, compared to analysts’ expectations of $166.14 million. Azenta had a positive return on equity of 0.89% and a negative net margin of 23.66%. The firm’s revenue was up 4.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.13 earnings per share. As a group, equities analysts anticipate that Azenta, Inc. will post 0.33 earnings per share for the current year.

Analyst Ratings Changes

AZTA has been the topic of several recent research reports. Evercore ISI dropped their target price on Azenta from $53.00 to $50.00 and set an “in-line” rating on the stock in a research report on Tuesday, October 1st. Needham & Company LLC reiterated a “buy” rating and issued a $69.00 price objective on shares of Azenta in a research report on Wednesday, August 7th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, Azenta has an average rating of “Hold” and an average target price of $66.40.

Insider Activity

In other news, CFO Herman Cueto sold 1,595 shares of the stock in a transaction dated Thursday, October 17th. The shares were sold at an average price of $43.68, for a total transaction of $69,669.60. Following the completion of the sale, the chief financial officer now directly owns 24,604 shares in the company, valued at approximately $1,074,702.72. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 1.77% of the company’s stock.

Azenta Profile

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.